Quantcast 7/13/13 - Genentech Secures FDA Priority Review For Perjeta Regimen Prior To Surgery - Congoo
 
 
BIOTECH Log In
7/13/13 - Genentech Secures FDA Priority Review for Perjeta Regimen Prior to Surgery
Have an interest in this Story?
Sign Up for Real-Time email updates
Pharmacy Choice  | July 13, 2013

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stag...
Read Full Article   
 
Leave a Comment: You must be logged in to leave a comment     Log in | Register
 

Featured Members
Melissa Keklak Melissa Keklak
Public Relations Manager
Marketing/Public Relations
Christopher O'Hara Christopher O'Hara
Senior Vice President
Online Marketing

  
  View more profiles

 
Access dozens of premium and subscriptions sites Free! Download now.

Advertise   |   Build a News Circle   |   Get News Briefings   |   Congoo News Home   |   Get the Netpass
About Congoo   |   Terms   |   Privacy   |   Need Help?   |   Site Map
Copyright ©2014 Congoo.com. All Rights Reserved.